Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Blueprint Medicines Corp (NQ: BPMC ) 90.15 +0.15 (+0.17%) Streaming Delayed Price Updated: 2:25 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Blueprint Medicines Corp < Previous 1 2 3 4 5 6 Next > 10 Biggest Price Target Changes For Wednesday June 01, 2022 Keybanc cut Ambarella, Inc. (NASDAQ: AMBA) price target from $160 to $120. Ambarella shares fell 5% to $81.00 in pre-market trading. Via Benzinga What 3 Analyst Ratings Have To Say About Blueprint Medicines May 19, 2022 Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: Via Benzinga The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs May 03, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga Blueprint Medicines: Q1 Earnings Insights May 03, 2022 Blueprint Medicines (NASDAQ:BPMC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Via Benzinga Earnings Scheduled For February 16, 2022 February 16, 2022 Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is projected to report quarterly loss at $0.38 per share on revenue of $331.16 million. Via Benzinga EMA's Advisory Committee Recommends Approval Of Blueprint Medicines' Avapritinib In Blood Disorder January 28, 2022 The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has Via Benzinga Analyst Ratings For Blueprint Medicines January 25, 2022 Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BP... Via Benzinga Earnings Preview: Blueprint Medicines May 02, 2022 Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga Blueprint Medicines Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET April 27, 2022 Blueprint Medicines (NASDAQ:BPMC) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. Via Benzinga Where Blueprint Medicines Stands With Analysts April 13, 2022 Over the past 3 months, 6 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with... Via Benzinga After Encouraging Data, Blueprint Medicines Plans Combination Cohort In Tagrisso Resistant Lung Cancer April 11, 2022 Blueprint Medicines Corp (NASDAQ: BPMC) Via Benzinga Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks March 09, 2022 Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many... Via Benzinga What 5 Analyst Ratings Have To Say About Blueprint Medicines March 01, 2022 Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and... Via Benzinga Stocks That Hit 52-Week Lows On Tuesday March 01, 2022 During Tuesday's trading, 98 companies set new 52-week lows. Intriguing Points From Today's 52-Week Lows And Highs: JPMorgan Chase (NYSE:JPM) was the... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 March 01, 2022 Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... Via Benzinga Blueprint Medicines, Proteovant Collaboration For Protein Degrader Therapies February 28, 2022 Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies.... Via Benzinga Stocks That Hit 52-Week Lows On Friday February 25, 2022 During Friday's trading, 54 companies set new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company by market cap to hit a new 52-week... Via Benzinga Stocks That Hit 52-Week Lows On Monday February 28, 2022 On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a... Via Benzinga Where Blueprint Medicines Stands With Analysts February 17, 2022 Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and... Via Benzinga The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa February 16, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... Via Benzinga Earnings Preview: Blueprint Medicines February 15, 2022 Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that... Via Benzinga The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More February 13, 2022 Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... Via Benzinga 10 Biggest Price Target Changes For Tuesday January 25, 2022 Needham cut Medtronic plc (NYSE:MDT) price target f... Via Benzinga Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer January 10, 2022 Pfizer and Bayer inked deals with several companies in gene-editing. Via Investor's Business Daily 50 Biggest Movers From Yesterday January 06, 2022 Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead... Via Benzinga 34 Stocks Moving In Wednesday's Mid-Day Session January 05, 2022 Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 49.7% to $15.45 after the company announced it acquired exclusive rights to novel mRNA biomarkers. Data Storage... Via Benzinga Blueprint Medicines Expands Precision Therapy With Lengo Therapeutics Acquisition November 29, 2021 Blueprint Medicines Corporation (NASDAQ: BPMC) has agreed to acquire Lengo Therapeutics, a privately held precision oncology company. The deal consideration... Via Benzinga Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million November 13, 2021 Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics. Via Talk Markets Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates November 09, 2021 Zai Lab Limited (NASDAQ: ZLAB) and Blueprint Medicines Corporation (NASDAQ: BPMC) have announced an exclusive collaboration and license agreement in... Via Benzinga Blueprint Medicines Corp (BPMC) Q3 2021 Earnings Call Transcript October 28, 2021 BPMC earnings call for the period ending September 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
